Media

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Vicore publishes the Annual Report for 2025

Intervacc announces breakthrough protection against Streptococcus suis infection in piglets

Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Outcome in Oncopeptides’ rights issue 

Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Oncopeptides – European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma

Positrigo Reaches Final of the Swiss Medtech Award 2026

First patient dosed in Gesynta Pharma’s endometriosis trial of vipoglanstat